Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older

Shilpa Biologicals and SteinCares ink strategic pact to bring biosimilars to Latin America

New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform

AbbVie to invest $380 million in new North Chicago manufacturing facilities

Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade

Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause

Artemis Medicare to manage 650-bed VIMHANS Hospital in Rs. 520 South Delhi expansion

The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore

BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal

FDA accepts Teva’s NDA for long-acting schizophrenia injection

If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations

Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg

Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension

Scinai acquires Recipharm Israel to expand global reach

This transaction fundamentally strengthens Scinai's CDMO platform

QCIL to build 350+ bed state-of-the-art CARE Hospital in Nagpur